Cerebral palsy (CP) is the most common motor disability in childhood, affecting approximately 2–3 per 1,000 live births worldwide. It is not a single disease but a group of permanent disorders of movement and posture caused by non-progressive damage to the developing brain — occurring before, during, or shortly after birth. For decades, the therapeutic landscape has been largely supportive: physical therapy, occupational therapy, orthotics, anti-spasticity medications, and in some cases, orthopedic or neurosurgical intervention. These approaches are essential for managing symptoms and maximizing function, but they do not address the underlying brain injury. Mesenchymal Stem Cell therapy represents a new frontier — one that aims to support neural repair, reduce neuroinflammation, and improve functional outcomes by targeting the biological processes that drive disability in CP.

Understanding what is happening in the brain in cerebral palsy

Cerebral palsy arises from injury to the developing brain — most commonly periventricular leukomalacia (white matter injury in preterm infants), hypoxic-ischemic encephalopathy, intraventricular hemorrhage, or perinatal stroke. The common thread is loss or dysfunction of oligodendrocytes, the cells responsible for producing myelin — the insulating sheath around nerve fibers that enables rapid, coordinated signal transmission. When myelin is damaged or underdeveloped, the motor signals traveling from the brain's motor cortex to the muscles are disrupted, resulting in the spasticity, dyskinesia, ataxia, and muscle weakness characteristic of CP.

Critically, the injury is not purely structural. There is a chronic neuroinflammatory component: activated microglia and astrocytes persist in the damaged brain regions, releasing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and reactive oxygen species that perpetuate tissue damage and inhibit endogenous repair mechanisms long after the initial insult. This ongoing inflammation contributes to the plateau in function that many children with CP experience — and it is precisely this inflammatory environment that MSC therapy is designed to modulate.[1]

Medical illustration of developing brain showing white matter injury patterns with activated microglia and reduced myelination
Cerebral palsy involves not just structural damage, but chronic neuroinflammation — a target MSC therapy is uniquely positioned to address.

How MSC therapy works in the brain

When clinical-grade Mesenchymal Stem Cells are delivered intravenously or intrathecally, they do not need to engraft permanently or replace neurons to exert therapeutic effects. Instead, they work through a coordinated set of paracrine mechanisms — releasing bioactive molecules that signal the brain's own repair systems:

1. Neuroinflammation modulation

MSCs respond to the inflammatory signals in the injured brain by secreting powerful anti-inflammatory mediators — TSG-6, PGE2, IL-10, and TGF-β. These molecules shift microglia from a pro-inflammatory (M1-like) to a neuroprotective (M2-like) phenotype, reducing the chronic inflammatory state that suppresses neural repair. This is arguably the most important mechanism by which MSCs improve function in CP.[2]

2. Neurotrophic support

MSCs secrete a rich cocktail of neurotrophic factors — BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), GDNF (glial-derived neurotrophic factor), and IGF-1. These molecules support the survival of existing neurons, promote synaptic plasticity, and create a permissive environment for neural circuit reorganization — the biological basis for functional improvement.[3]

3. Oligodendrocyte protection and myelination support

MSC-derived factors protect oligodendrocyte precursor cells from apoptosis and encourage their differentiation into mature, myelin-producing oligodendrocytes. In animal models of neonatal brain injury, MSC treatment has been shown to increase myelination and improve motor outcomes — a finding that has driven clinical interest in CP.[4]

4. Angiogenesis and perfusion

MSCs secrete VEGF and other angiogenic factors that support the formation of new blood vessels in damaged brain regions, improving oxygen and nutrient delivery to recovering neural tissue.

5. Anti-apoptotic signaling

MSC paracrine factors activate survival pathways (PI3K/Akt, MAPK/ERK) in threatened neurons and glial cells, reducing programmed cell death in the penumbra of the original injury.

What MSC therapy does NOT do

It is important to set honest expectations. MSC therapy does not cure cerebral palsy. It does not regenerate large areas of lost brain tissue or reverse fixed structural damage. What it does — based on a growing body of clinical evidence — is reduce neuroinflammation, support neural plasticity, improve motor function, reduce spasticity, and in many cases, enhance quality of life in ways that conventional therapies alone cannot achieve. The goal is functional improvement, not a cure — and the most meaningful outcomes are seen when MSC therapy is combined with intensive rehabilitation.[5]

What the clinical evidence says

The clinical evidence base for MSC therapy in cerebral palsy has grown substantially over the past decade, with multiple published trials — including randomized controlled studies — reporting measurable functional improvements:[6]

It is important to note that while the overall direction of evidence is positive, individual responses vary significantly — influenced by age at treatment, type and severity of CP, MSC source and dose, delivery route, and the intensity of concurrent rehabilitation. The strongest outcomes are typically seen in younger children with greater baseline neuroplasticity.[7]

Child receiving gentle physical therapy combined with IV stem cell infusion in a clinical treatment room
MSC therapy is most effective when combined with structured rehabilitation — the two work synergistically to maximize functional gains.

Who is a good candidate?

The evidence suggests that a broad range of CP patients may benefit from MSC therapy, but certain characteristics are associated with stronger outcomes:[8]

Patients with severe, fixed joint contractures, uncontrolled epilepsy, or progressive neurological conditions (which would suggest a diagnosis other than CP) require careful evaluation. A reputable clinic will conduct thorough neurological assessment, review brain imaging, and provide honest guidance about expected outcomes before proceeding.[9]

What the treatment process looks like

At a clinical-grade centre, a typical CP-focused MSC therapy journey follows a structured, multidisciplinary path:

Step 1: Comprehensive assessment

Neurological examination, review of brain MRI, GMFCS classification, functional assessment (typically GMFM-66), spasticity evaluation (Modified Ashworth Scale), and review of medical history, including seizure control and current medications.

Step 2: Protocol design

The clinical team determines cell dose (typically weight-based), delivery route (IV infusion, intrathecal injection, or combined), session frequency (single vs. multiple sessions over 3–6 months), and the rehabilitation plan that will follow each treatment session.

Step 3: Treatment delivery

IV infusion is the most common route — typically 60–90 minutes, outpatient, with monitoring during and after administration. Intrathecal delivery may be used in specific cases for more direct CNS access. Sessions are generally well-tolerated, with most children returning to normal activities within 24 hours.

Step 4: Intensive rehabilitation

This is a critical component. The neuroplasticity window following MSC treatment is optimized by structured physical therapy, occupational therapy, and where appropriate, speech therapy. The strongest outcomes come when MSC therapy and rehabilitation are tightly integrated — not delivered sequentially, but as a combined protocol.

Step 5: Outcome monitoring

Follow-up at 1, 3, 6, and 12 months tracks motor function (GMFM-66), spasticity (Modified Ashworth), functional independence (WeeFIM or PEDI), and in some cases, repeat neuroimaging. Maintenance sessions may be recommended based on individual response patterns.

Realistic timelines: what to expect when

Cellular therapy for a neurodevelopmental condition follows a different trajectory than for orthopedic or inflammatory conditions. The brain's repair processes are slower but potentially more transformative:[10]

2–4 weeks Initial reduction in spasticity and improved sleep patterns often reported first
8–12 weeks Measurable motor function improvements — head control, sitting, grasping, gait
6–12 months Sustained functional gains, improvements in communication and social interaction

It is essential to understand that progress in CP is typically incremental — not dramatic overnight transformations, but meaningful, cumulative gains in motor control, spasticity reduction, and functional independence. The most important predictor of outcome is the combination of quality MSC therapy with consistent, intensive rehabilitation. Families who commit to both see the strongest results.[11]

Safety and what every family should know

When delivered with clinical-grade cells, appropriate dosing, and medical supervision, MSC therapy has demonstrated a strong safety profile in pediatric populations. The most common side effects are transient: mild fever (typically within 24 hours of infusion), temporary fatigue, or mild headache — all self-limiting. Serious adverse events are rare in published pediatric CP trials.[12]

The greatest preventable risk in this field is unregulated providers using non-clinical-grade cells with unverified sterility, identity, or potency — particularly concerning in pediatric patients. Families should always confirm: MSC source (Wharton's jelly, bone marrow, or adipose), laboratory certifications (GMP, ISO), cell characterization (ISCT criteria: ≥95% CD73/CD90/CD105 positive), viability (>90% post-thaw), and sterility testing. A Certificate of Analysis for the specific dose being administered should be available upon request.[13]

For families living with cerebral palsy, MSC therapy is not about unrealistic promises — it is about expanding the window of neuroplasticity and giving rehabilitation a biological partner. The gains are measured in small, meaningful increments that, over time, can change the trajectory of a child's development.

— VELAR Clinical Team

The VELAR approach to cerebral palsy

CP protocols at VELAR Center begin with comprehensive neurological assessment, brain MRI review, GMFCS classification, and functional evaluation to confirm candidacy and personalize dosing. Each protocol uses clinical-grade Wharton's jelly–derived MSCs (≥95% MSC marker expression, >90% post-thaw viability), delivered via IV infusion with intrathecal options where clinically indicated. Every session is physician-led, paired with structured rehabilitation, and monitored across the 1, 3, 6, and 12-month milestones. The VELAR team works closely with the child's existing therapy team to ensure continuity of care and integrated rehabilitation.[14]

If you are considering regenerative therapy for a child with cerebral palsy, the most important first step is an honest, thorough assessment of candidacy — and a clear conversation about what realistic outcomes look like for your child's specific type and severity of CP.

References

  1. Graham HK, Rosenbaum P, Paneth N, et al. Cerebral palsy. Nature Reviews Disease Primers. 2016;2:15082. doi:10.1038/nrdp.2015.82 ↩
  2. Ahn SY, Chang YS, Sung DK, et al. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke. 2013;44(2):497-504. doi:10.1161/STROKEAHA.112.679092 ↩
  3. Park WS, Ahn SY, Sung SI, Ahn JY, Chang YS. Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders. Pediatric Research. 2018;83(1-2):214-222. doi:10.1038/pr.2017.249 ↩
  4. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain, Behavior, and Immunity. 2010;24(3):387-393. doi:10.1016/j.bbi.2009.10.017 ↩
  5. Novak I, Walker K, Hunt RW, Wallace EM, Fahey M, Badawi N. Concise review: stem cell interventions for people with cerebral palsy: systematic review with meta-analysis. Stem Cells Translational Medicine. 2016;5(8):1014-1025. doi:10.5966/sctm.2015-0372 ↩
  6. Min K, Song J, Kang JY, et al. Umbilical cord blood therapy potentiated by erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013;31(3):581-591. doi:10.1002/stem.1304 ↩
  7. Sun JM, Song AW, Case LE, et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Translational Medicine. 2017;6(12):2071-2078. doi:10.1002/sctm.17-0102 ↩
  8. Rah WJ, Lee YH, Moon JH, et al. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood mononuclear cells in children with cerebral palsy. Journal of Translational Medicine. 2017;15(1):28. doi:10.1186/s12967-017-1128-5 ↩
  9. Feng M, Lu A, Gao H, et al. Safety of allogeneic umbilical cord blood stem cells therapy in patients with severe cerebral palsy: a retrospective study. Stem Cells International. 2015;2015:325652. doi:10.1155/2015/325652 ↩
  10. Jensen A, Hamelmann E. First autologous cell therapy of cerebral palsy caused by hypoxic-ischemic brain damage in a child after cardiac arrest — individual treatment with cord blood. Case Reports in Transplantation. 2013;2013:951827. doi:10.1155/2013/951827 ↩
  11. Boruczkowski D, Zdolinska-Malinowska I. Wharton's jelly mesenchymal stem cell administration improves quality of life and self-sufficiency in children with cerebral palsy: results from a retrospective study. Stem Cells International. 2019;2019:7402151. doi:10.1155/2019/7402151 ↩
  12. Lv ZY, Li Y, Liu J. Progress in clinical trials of stem cell therapy for cerebral palsy. Neural Regeneration Research. 2021;16(7):1377-1382. doi:10.4103/1673-5374.300979 ↩
  13. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  14. Gu J, Huang L, Zhang C, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Research & Therapy. 2020;11(1):43. doi:10.1186/s13287-019-1545-x ↩